New Applications of Tumor-Associated Antigens in the Diagnosis and Therapy of Cancer

Kuroki, Masahide; Shibaguchi, Hirotomo; Hachimine, Ken; Badran, Adel; Zhang, Jitian; Yamada, Hiromi; Hirose, Yuki

doi:10.2468/jbes.55.55

Cited by 10 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, the serum CEA levels may be monitored to detect a response to anticancer therapy or disease recurrence in various cancers, especially in colorectal cancer (Goldstein Mitchell, 2005;Locker et al, 2006). Immunohistochemical staining of CEA using surgically-or biopsy-removed specimens is also helpful as a diagnostic aid in patients with various cancers (Kuroki et al, 2002). Prognosis Serum CEA serves as a prognostic indicator in patients with various types of cancer, where elevated levels indicate a poor prognosis and correlate with a reduced overall survival (Duffy, 2001;Locker et al, 2006).…”

Section: Notementioning

confidence: 99%

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5 (carcinoembryonic antigen))

Shirasu¹,

Kuroki²

2017

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Notementioning

confidence: 99%

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5 (carcinoembryonic antigen))

Shirasu¹,

Kuroki²

2017

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…TAs are often used as targets for therapeutic approaches against cancer [2]. In this context, TAs can be categorized into three types: (i) those that are directly expressed on the surface of tumor cells and are identified by heteroantibodies or autoantibodies, i.e.…”

Section: Introductionmentioning

confidence: 99%

“…These altered HLA class I phenotypes and the non-ubiquitous expression of the target molecules for NK receptor constitute the major tumor escape mechanism facing tumor-specific CTL-and/or NK-cell-mediated responses. This suggests that it is not easy to eliminate the target tumors by activating tumor-specific CTLs or NK cells in patients, or by adoptively transferring ex vivo activated CTLs or NK cells into patients [2]. In contrast, the expression of antibody-recognized TAs such as CEA on the cell surface of target tumor cells is easily confirmed by immunostaining and/or flow cytometry using the corresponding antibodies [8].…”

Section: Introductionmentioning

confidence: 99%

“…Many TAs can be grouped into the two former categories [2]. For example, carcinoembryonic antigen (CEA), originally identified by rabbit antibodies [3], is sufficiently immunogenic to elicit humoral immunity (antibody production; fig.…”

Section: Introductionmentioning

confidence: 99%

“…T-cell immunotherapy is based on the assumption that the TA peptides recognized by T-cell receptors (TCRs) are correctly presented by HLA class I molecules on target tumor cells [2], while NK cell immunotherapy is based on the hypothesis that cell surface TAs for NK receptors are widely expressed in tumor cells [5]. However, HLA class I molecules are frequently downregulated or lost during the development of malignancies [6,7], and ubiquitous expression of NK receptor ligands on tumor cells has not been identified [5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Strategies to Endow Cytotoxic T Lymphocytes or Natural Killer Cells with Antibody Activity against Carcinoembryonic Antigen

Kuroki¹,

Shibaguchi²,

Badran³

et al. 2004

Tumor Biol

Self Cite

View full text Add to dashboard Cite

Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are main effecter cells in cellular immunity against tumor cells. T-cell immunotherapy is based on the assumption that tumor(-associated) antigen (TA) peptides are correctly presented by HLA class I molecules on target tumor cells, and NK cell immunotherapy is based on the hypothesis that cell surface TAs or ligands for NK receptors are widely expressed in tumor cells. However, human tumor cells often lose HLA class I molecules, and target cell ligands for NK receptors are not always expressed in human tumor cells. These altered HLA class I phenotypes and non-ubiquitous expression of NK receptor ligands constitute the major tumor escape mechanism facing tumor-specific CTL and/or NK cell mediated responses. These facts also indicate that it is not easy to eliminate the target tumors only by activating tumor-specific CTLs or NK cells with cancer vaccine treatments. On the other hand, it is easily confirmed by immunohistochemistry whether or not antibody-recognized TAs exist on the cell surface of target tumor cells. Therefore, endowing CTLs or NK cells with antigen-binding specificity of anti-TA antibody is a promising approach for re-targeting the activities of these effector cells to tumor cells in an HLA-independent manner. This review summarizes the following four new strategies for re-targeting CTLs or NK cells to carcinoembryonic-antigen-expressing tumor cells: (1) bispecific antibody technology; (2) antibody-cytokine fusion protein technology; (3) chimeric immune receptor technology, and (4) antibody-HLA/peptide complex technology.

show abstract

The effect of a low‐fat, high fiber, fruit and vegetable intervention on rectal mucosal proliferation

Pfeiffer

McShane

Wargovich

et al. 2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDBecause studies of diet and colorectal carcinoma tend to be large and complex, researchers have long been interested in the investigation of dietary exposures in relation to putative intermediate markers of large bowel malignancy, such as colorectal epithelial cell proliferation. The basic hypothesis underlying these investigations is that specific dietary components may reduce or increase the rate of cell proliferation, which, in turn, may reduce or increase neoplastic changes in the large bowel.METHODSThe authors assessed the effects of a 4‐year, low‐fat, high‐fiber, fruit and vegetable‐enriched dietary intervention on colorectal epithelial cell proliferation among 399 participants from the Polyp Prevention Trial, a randomized multicenter trial with adenoma recurrence as the primary endpoint. Rectal biopsies were taken from flat, normal appearing mucosa on patients at baseline, after 1 year, and after 4 years. Two assays, bromodeoxyuridine (Brd U) and proliferating cell nuclear antigen (PCNA), were used to evaluate two summary measures of proliferation: the labeling index (LI) and the proliferative height (PH).RESULTSThere were no significant differences between changes in LI and PH over the 4‐year period for the intervention and control groups. This finding parallels the finding in the larger primary study, in which the dietary intervention did not alter adenoma recurrence rates.CONCLUSIONSA low‐fat, high‐fiber, fruit and vegetable‐enriched dietary intervention did not alter rectal mucosal cell proliferation rates. Cancer 2003;98:1161–8. Published 2003 by the American Cancer Society.DOI 10.1002/cncr.11608

show abstract

New Applications of Tumor-Associated Antigens in the Diagnosis and Therapy of Cancer

Cited by 10 publications

References 12 publications

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5 (carcinoembryonic antigen))

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5 (carcinoembryonic antigen))

Strategies to Endow Cytotoxic T Lymphocytes or Natural Killer Cells with Antibody Activity against Carcinoembryonic Antigen

The effect of a low‐fat, high fiber, fruit and vegetable intervention on rectal mucosal proliferation

Contact Info

Product

Resources

About